About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:5316370
Allelic
Composition		 Ebf1tm1.1Rug/Ebf1tm1.1Rug
Polr2atm1(cre/ERT2)Bbd/Polr2a+
Genetic
Background		 involves: C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ebf1tm1.1Rug mutation (0 available); any Ebf1 mutation (73 available)
Polr2atm1(cre/ERT2)Bbd mutation (3 available); any Polr2a mutation (92 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
immune system
immune system phenotype ( J:182210 )
N
• tamoxifen-treated mice exhibit normal somatic hypermutation
increased B cell apoptosis ( J:182210 )
• tamoxifen-treated pro-B cells exhibit reduced survival compared with wild-type mice that cannot be rescued by expression of Bcl2 or Foxo1 or transformation with A-MuLV
• stimulated B cells from tamoxifen-treated mice exhibit reduced survival compared with control cells
• however, expression of Myb or BAFF rescues B cell survival and expression of Bcl2l1 partially rescues B survival
decreased B cell proliferation ( J:182210 )
• with cell cycle defects in tamoxifen-treated mice
• of B cells from tamoxifen-treated mice stimulated with LPS, CpG or anti-IgM
• tamoxifen-treated mice exhibit impaired germinal center formation and germinal center B cell proliferation compared with control mice
• however, B cell proliferation is rescued by transformation with A-MuLV
decreased immature B cell number ( J:182210 )
• in tamoxifen-treated mice
decreased transitional stage B cell number ( J:182210 )
• in tamoxifen-treated mice
arrested B cell differentiation ( J:182210 )
• of pre-B cells from tamoxifen-treated mice in vitro
decreased germinal center B cell number ( J:182210 )
• in tamoxifen-treated mice, less severe 12 days after immunization
decreased marginal zone B cell number ( J:182210 )
• in tamoxifen-treated mice
decreased pre-B cell number ( J:182210 )
• reduced frequency of B220intCD43- pre-B cells in tamoxifen-treated mice
increased B cell number ( J:182210 )
• increased number of recirculating B220hiCD43- B cells in tamoxifen-treated mice
decreased spleen germinal center number ( J:182210 )
• in immunized tamoxifen-treated mice
abnormal germinal center B cell physiology ( J:182210 )
• tamoxifen-treated mice exhibit impaired germinal center formation and germinal center B cell proliferation compared with control mice
decreased IgG1 level ( J:182210 )
• by a factor of 5 in tamoxifen treated mice
decreased IgG3 level ( J:182210 )
• by a factor of 3 in tamoxifen treated mice

cellular
increased B cell apoptosis ( J:182210 )
• tamoxifen-treated pro-B cells exhibit reduced survival compared with wild-type mice that cannot be rescued by expression of Bcl2 or Foxo1 or transformation with A-MuLV
• stimulated B cells from tamoxifen-treated mice exhibit reduced survival compared with control cells
• however, expression of Myb or BAFF rescues B cell survival and expression of Bcl2l1 partially rescues B survival
decreased B cell proliferation ( J:182210 )
• with cell cycle defects in tamoxifen-treated mice
• of B cells from tamoxifen-treated mice stimulated with LPS, CpG or anti-IgM
• tamoxifen-treated mice exhibit impaired germinal center formation and germinal center B cell proliferation compared with control mice
• however, B cell proliferation is rescued by transformation with A-MuLV

hematopoietic system
increased B cell apoptosis ( J:182210 )
• tamoxifen-treated pro-B cells exhibit reduced survival compared with wild-type mice that cannot be rescued by expression of Bcl2 or Foxo1 or transformation with A-MuLV
• stimulated B cells from tamoxifen-treated mice exhibit reduced survival compared with control cells
• however, expression of Myb or BAFF rescues B cell survival and expression of Bcl2l1 partially rescues B survival
decreased B cell proliferation ( J:182210 )
• with cell cycle defects in tamoxifen-treated mice
• of B cells from tamoxifen-treated mice stimulated with LPS, CpG or anti-IgM
• tamoxifen-treated mice exhibit impaired germinal center formation and germinal center B cell proliferation compared with control mice
• however, B cell proliferation is rescued by transformation with A-MuLV
decreased immature B cell number ( J:182210 )
• in tamoxifen-treated mice
decreased transitional stage B cell number ( J:182210 )
• in tamoxifen-treated mice
arrested B cell differentiation ( J:182210 )
• of pre-B cells from tamoxifen-treated mice in vitro
decreased germinal center B cell number ( J:182210 )
• in tamoxifen-treated mice, less severe 12 days after immunization
decreased marginal zone B cell number ( J:182210 )
• in tamoxifen-treated mice
decreased pre-B cell number ( J:182210 )
• reduced frequency of B220intCD43- pre-B cells in tamoxifen-treated mice
increased B cell number ( J:182210 )
• increased number of recirculating B220hiCD43- B cells in tamoxifen-treated mice
decreased spleen germinal center number ( J:182210 )
• in immunized tamoxifen-treated mice
abnormal germinal center B cell physiology ( J:182210 )
• tamoxifen-treated mice exhibit impaired germinal center formation and germinal center B cell proliferation compared with control mice
decreased IgG1 level ( J:182210 )
• by a factor of 5 in tamoxifen treated mice
decreased IgG3 level ( J:182210 )
• by a factor of 3 in tamoxifen treated mice

Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
04/30/2024
MGI 6.23 		The Jackson Laboratory